243 related articles for article (PubMed ID: 27793696)
1. Baseline MAPK signaling activity confers intrinsic radioresistance to KRAS-mutant colorectal carcinoma cells by rapid upregulation of heterogeneous nuclear ribonucleoprotein K (hnRNP K).
Eder S; Arndt A; Lamkowski A; Daskalaki W; Rump A; Priller M; Genze F; Wardelmann E; Port M; Steinestel K
Cancer Lett; 2017 Jan; 385():160-167. PubMed ID: 27793696
[TBL] [Abstract][Full Text] [Related]
2. Radiosensitization and downregulation of heterogeneous nuclear ribonucleoprotein K (hnRNP K) upon inhibition of mitogen/extracellular signal-regulated kinase (MEK) in malignant melanoma cells.
Eder S; Lamkowski A; Priller M; Port M; Steinestel K
Oncotarget; 2015 Jul; 6(19):17178-91. PubMed ID: 26136337
[TBL] [Abstract][Full Text] [Related]
3. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
[TBL] [Abstract][Full Text] [Related]
4. Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway.
Chu PC; Lin PC; Wu HY; Lin KT; Wu C; Bekaii-Saab T; Lin YJ; Lee CT; Lee JC; Chen CS
Oncogene; 2018 Jun; 37(25):3440-3455. PubMed ID: 29559746
[TBL] [Abstract][Full Text] [Related]
5. Expression levels of hnRNP K and p21WAF1/CIP1 are associated with resistance to radiochemotherapy independent of p53 pathway activation in rectal adenocarcinoma.
Daskalaki W; Wardelmann E; Port M; Stock K; Steinestel J; Huss S; Sperveslage J; Steinestel K; Eder S
Int J Mol Med; 2018 Dec; 42(6):3269-3277. PubMed ID: 30272263
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous nuclear ribonucleoprotein K is overexpressed and contributes to radioresistance irrespective of HPV status in head and neck squamous cell carcinoma.
Kähler J; Hafner S; Popp T; Hermann C; Rump A; Port M; Steinestel K; Eder S
Int J Mol Med; 2020 Nov; 46(5):1733-1742. PubMed ID: 32901844
[TBL] [Abstract][Full Text] [Related]
7. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
[TBL] [Abstract][Full Text] [Related]
8. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.
Pek M; Yatim SMJM; Chen Y; Li J; Gong M; Jiang X; Zhang F; Zheng J; Wu X; Yu Q
Oncogene; 2017 Aug; 36(35):4975-4986. PubMed ID: 28459468
[TBL] [Abstract][Full Text] [Related]
10. Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.
Haagensen EJ; Thomas HD; Mudd C; Tsonou E; Wiggins CM; Maxwell RJ; Moore JD; Newell DR
Eur J Cancer; 2016 Mar; 56():69-76. PubMed ID: 26820797
[TBL] [Abstract][Full Text] [Related]
11. Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy.
Alves S; Castro L; Fernandes MS; Francisco R; Castro P; Priault M; Chaves SR; Moyer MP; Oliveira C; Seruca R; Côrte-Real M; Sousa MJ; Preto A
Oncotarget; 2015 Oct; 6(31):30787-802. PubMed ID: 26418750
[TBL] [Abstract][Full Text] [Related]
12. Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells.
Cheon SK; Kim HP; Park YL; Jang JE; Lim Y; Song SH; Han SW; Kim TY
Mol Oncol; 2018 Aug; 12(8):1398-1409. PubMed ID: 29896883
[TBL] [Abstract][Full Text] [Related]
13. hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage.
Moumen A; Masterson P; O'Connor MJ; Jackson SP
Cell; 2005 Dec; 123(6):1065-78. PubMed ID: 16360036
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA CASC11 interacts with hnRNP-K and activates the WNT/β-catenin pathway to promote growth and metastasis in colorectal cancer.
Zhang Z; Zhou C; Chang Y; Zhang Z; Hu Y; Zhang F; Lu Y; Zheng L; Zhang W; Li X; Li X
Cancer Lett; 2016 Jun; 376(1):62-73. PubMed ID: 27012187
[TBL] [Abstract][Full Text] [Related]
15. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
Temraz S; Mukherji D; Shamseddine A
Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261
[TBL] [Abstract][Full Text] [Related]
16. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
[TBL] [Abstract][Full Text] [Related]
17. [Association of epithermal growth factor receptor expression and its downstream gene mutation status with radiosensitivity of colorectal carcinoma cell lines in vitro].
Zuo ZG; Yu ZQ; Gao XH; Wang H; Zhang C; Liu QZ; Han YF; Chen LP; Zhang XQ; Fu CG
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Aug; 16(8):753-8. PubMed ID: 23980047
[TBL] [Abstract][Full Text] [Related]
18. MiR-106b induces cell radioresistance via the PTEN/PI3K/AKT pathways and p21 in colorectal cancer.
Zheng L; Zhang Y; Liu Y; Zhou M; Lu Y; Yuan L; Zhang C; Hong M; Wang S; Li X
J Transl Med; 2015 Aug; 13():252. PubMed ID: 26238857
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair.
Yang L; Shen C; Estrada-Bernal A; Robb R; Chatterjee M; Sebastian N; Webb A; Mo X; Chen W; Krishnan S; Williams TM
Nucleic Acids Res; 2021 Nov; 49(19):11067-11082. PubMed ID: 34606602
[TBL] [Abstract][Full Text] [Related]
20. MiR-185 enhances radiosensitivity of colorectal cancer cells by targeting IGF1R and IGF2.
Afshar S; Najafi R; Sedighi Pashaki A; Sharifi M; Nikzad S; Gholami MH; Khoshghadam A; Amini R; Karimi J; Saidijam M
Biomed Pharmacother; 2018 Oct; 106():763-769. PubMed ID: 29990869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
